Mesenchymal Stem Cell Conditioned Medium for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The availability of mesenchymal stem cells (MSCs) for therapeutic use is limited by the need for invasive tissue isolation and finite ex vivo expansion, and the efficiency of transplanted MSCs to differentiate into functional reparative cells in injured tissues has not been adequately documented.
Innovation Solution
The use of conditioned media from human embryonic stem cell-derived MSCs, which contains biologically active compounds, to enhance endogenous tissue repair instead of or in addition to MSCs themselves, potentially providing 'off-the-shelf' therapeutics with better quality control and consistency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are isolated from adult tissues, then therapeutic efficacy is achieved, but invasive procedures and limited availability occur
Solution Approach 1:
The invention extracts the therapeutic essence of MSCs by isolating and culturing them from embryonic stem cells rather than requiring direct isolation from adult tissues. This extracts the beneficial cellular properties while eliminating the need for invasive tissue sampling procedures
Solution Approach 2:
The invention performs preliminary expansion and differentiation of MSCs from embryonic stem cells before clinical use. This preliminary action allows cells to be prepared in advance under controlled conditions, eliminating the need for invasive procedures at the time of treatment
2Quantity of substance
If mesenchymal stem cells are expanded ex vivo, then cell availability increases, but expansion capacity remains finite
Solution Approach 1:
The invention performs preliminary expansion of MSCs from embryonic stem cells before clinical use, allowing large numbers of cells to be generated in advance under optimized culture conditions, thereby overcoming the finite expansion capacity of directly isolated adult MSCs
3Reliability
If transplanted mesenchymal stem cells are used, then tissue repair is promoted, but differentiation efficiency is insufficient
Solution Approach 1:
The invention applies local quality by differentiating MSCs into specific cell types (adipocytes, chondrocytes, osteocytes) according to the specific tissue repair needs. This targeted differentiation ensures that the right cell type is delivered to the right location with appropriate functional properties
Solution Approach 2:
The invention performs preliminary differentiation of MSCs into specific reparative cell types before transplantation. This preliminary action ensures that cells arrive at the injury site with predetermined differentiation status, enhancing their immediate therapeutic effectiveness
4Reliability
If autologous mesenchymal stem cell preparations are used, then immune compatibility is achieved, but cost and waiting time increase
Solution Approach 1:
The invention creates universal MSC preparations from embryonic stem cells that can serve multiple patients. These allogeneic MSCs are immunomodulatory and can be used across different recipients, eliminating the need for individual autologous preparations while reducing time and cost
Solution Approach 2:
The invention creates standardized MSC products that can be replicated and distributed to multiple patients. Instead of creating unique autologous preparations for each patient, standardized cell lines are cultured and distributed, significantly reducing preparation time and cost while maintaining therapeutic efficacy
Data Source
AI summary
We disclose a method of preparing a conditioned cell culture medium, the method comprising the steps of: (a) culturing a mesenchymal stem cell (MSC), a descendent thereof or a cell line derived therefrom in a cell culture medium; and (b) optionally isolating the cell culture medium; in which the mesenchymal stem cell (MSC) is obtained by propagating a cell obtained by dispersing a embryonic stem (ES) cell colony, or a descendent thereof, in the absence of co-culture in a serum free medium comprising FGF2.